Articles tagged with Ovarian Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
Women who inherit BRCA1 or BRCA2 gene mutations from their father are at increased risk of breast and ovarian cancer, yet this risk is often overlooked. A study found that patients with a paternal family history of cancer were 5 times more likely to be referred for genetic testing than those with a maternal family history.
A new study found that estrogen replacement therapy significantly speeds up ovarian cancer growth and increases the likelihood of cancer metastasizing to the lymph nodes. Researchers discovered estrogen-regulated genes specific to ER+ ovarian cancer that can be targeted with new anti-estrogen therapies.
A renowned gynecologic oncologist expresses concerns about a major ovarian cancer study, highlighting the need for targeted genetics-based treatments over delayed treatment timing. The study found no significant difference in survival rates between early and delayed chemotherapy groups.
A randomized study found that adding topotecan to carboplatin and paclitaxel did not improve progression-free survival in patients with ovarian cancer, but increased toxicity. The standard regimen of carboplatin and paclitaxel remains the best care for epithelial ovarian cancer.
A Phase II clinical trial of MLN8237, a selective Aurora A kinase inhibitor, demonstrates single-agent activity with durable disease control in some patients with ovarian cancer resistant to platinum-based chemotherapy. The study found encouraging responses in several patients, suggesting potential for future combination therapies.
A molecular imaging technique may help identify early response to treatment in cisplatin-resistant ovarian cancer, potentially reducing unnecessary side effects and offering more effective treatments. Researchers used a PET probe to monitor tumor growth in mice with human ovarian cancer.
A new randomised trial shows that starting chemotherapy earlier does not improve survival or quality of life for women with relapsed ovarian cancer. The study found that patients who received early treatment experienced a faster deterioration in quality of life, including role, emotional, social, and fatigue symptoms.
Research published in Annals of Oncology suggests that intrauterine devices releasing progestin hormone levonorgestrel combined with GnRH injections can halt and reverse cancer growth in women aged 40 or younger. The treatment has shown promise in treating specific types of endometrial cancer, preserving fertility for young women.
Two studies found new genetic variants linked to ovarian cancer risk in the general population, particularly in women with serous ovarian cancer. The variants were more common in women with aggressive disease and may be used for closer surveillance and preventive approaches.
A consortium of cancer researchers has identified four chromosome locations with genetic changes that may alter a woman's risk of developing ovarian cancer. These findings are based on a large genome-wide association study and could lead to individualized risk assessments for ovarian cancer.
Researchers have identified two genes, ARID1A and PPP2R1A, whose mutations are linked to ovarian clear cell carcinoma, a highly aggressive form of ovarian cancer. The study found that ARID1A mutations were present in over half of the tumors studied, suggesting a significant role in this type of cancer.
A long-term study found that women with BRCA1 and BRCA2 genetic mutations significantly reduced their risk of breast and ovarian cancer with preventive surgeries. Risk-reducing mastectomies and removal of the fallopian tubes and ovaries lowered cancer risks, including those with prior breast cancer.
Prophylactic mastectomy and salpingo-oophorectomy significantly reduce breast and ovarian cancer risks in women with BRCA1/2 mutations. The study found that risk-reducing mastectomy decreased breast cancer risk, while salpingo-oophorectomy lowered ovarian cancer risk.
Women with a family history of breast or ovarian cancer can benefit from prophylactic surgeries to remove ovaries, fallopian tubes, or breasts, increasing survival rates and eliminating risk. Genetic testing is crucial for identifying the BRCA1 and BRCA2 genes, which significantly increase cancer risk.
The study found that depleting SIK2 from ovarian cancers sensitized the cells to paclitaxel, making it more effective in stopping cancer growth. Levels of SIK2 protein are increased in approximately 30 percent of ovarian cancers and associated with poorer survival rates.
Researchers have discovered a protein called Salt Inducible Kinase 2 (SIK2) that plays a key role in regulating cell division and may be an attractive target for treating ovarian cancer. Combination therapies targeting different phases of the cell cycle are highly desirable for optimal cancer treatment.
Researchers found that EZH2 promotes tumor growth by shutting down genes that block formation of new blood vessels. Silencing EZH2 in ovarian cancer tumors reduced average tumor weight by 62% and increased programmed death of tumor cells.
Despite advancements in cancer biomarker research, many initial breakthroughs fail to translate to clinical success due to issues with study design and interpretation. Seven biomarkers initially hailed as promising have been reevaluated, highlighting problems with pre-analytical, analytical, and post-analytical study design.
A recent study suggests that a new drug, Olaparib, can reduce tumor size in women with advanced hereditary ovarian and breast cancers, offering a promising targeted therapy approach. The Phase II trials showed significant shrinkage in tumor size and relatively mild toxicities.
The new test uses mass spectrometry to analyze metabolites in a single drop of blood serum, accurately identifying women with ovarian cancer in all tested patients. Further testing will be conducted on 500 patients to confirm the results and explore its potential for detecting other types of cancers.
Researchers at Yale University have discovered a genetic marker that can help predict ovarian cancer risk. The KRAS-variant was found in 25% of all ovarian cancer patients and 61% of those with a family history of breast and ovarian cancer, suggesting it may be a new marker for high-risk families.
A new study reveals that shorter leukocyte telomere length is associated with a significantly increased risk of developing cancer and dying from cancer. Participants with the shortest telomere lengths had approximately three times the risk of cancer compared to those in the longest group.
Researchers at TGen have found a way to revive chemotherapy in ovarian cancer patients who no longer respond to conventional treatment. By inhibiting the CHEK1 protein, they were able to make these cells sensitive again to cisplatin, a widely used platinum-based chemotherapy drug.
Two phase-2 trials demonstrate the efficacy of olaparib in treating advanced ovarian and breast cancer in patients with BRCA1 or BRCA2 mutations. The higher dose of olaparib showed better treatment response rates compared to the lower dose, with ORR of 33% and 41% respectively.
Researchers at Arizona State University and Fred Hutchinson Cancer Research Center develop a new method to identify biomarkers for ovarian cancer using antibodies. They found 19 distinct scFvs that selectively bound to proteins exclusively found in ovarian cancerous blood serum, providing potential for significant improvements in patie...
A phase I clinical trial of the combination of decitabine and carboplatin has shown promising results in treating late-stage ovarian cancer, with four patients experiencing no disease progression after six months. The treatment regimen has been found to be well-tolerated, with mild adverse reactions.
A new treatment regimen combining bevacizumab with standard chemotherapy significantly extends progression-free survival for women with advanced ovarian cancer, reducing disease worsening to 14.1 months compared to 10.3 months. The trial results also point to the possibility of more personalized and effective treatment in the future.
Researchers found that CA-125 change over time can detect invasive, high-grade ovarian cancers at curable stages in post-menopausal women. The study identified a promising first step towards screening, but acknowledges the need for further research and a large-scale randomized trial to confirm the findings.
Researchers found that flaxseed-enriched diets decreased late-stage ovarian tumor severity and increased survival rates in hens. The study also showed improved weight control and reduced metastatic spread in hens fed the flaxseed diet, suggesting potential benefits for human ovarian cancer treatment.
Researchers found that curcumin nanoparticles, delivered via nanoparticles, increased the sensitivity of resistant ovarian cancer cells to chemotherapy and radiation. The treatment enables lower doses of cisplatin and radiation, improving therapeutic outcomes without increasing toxicity.
Fox Chase researchers have discovered that early ovarian cancers arise in inclusion cysts of the ovary. The team found gene expression patterns and extra chromosomes in cells from these cysts compared to normal surface epithelium cells.
Researchers have identified a new breast and ovarian cancer susceptibility gene, RAD51C, in a German study. The gene is associated with a high risk of breast and ovarian cancer, particularly in familial cases.
Researchers have found that patients with hereditary ovarian cancer are more likely to experience secondary tumours in their liver and spleen, despite better overall prognosis. A new approach suggests testing these patients for BRCA1 and BRCA2 genes to ensure tailored treatment.
The Anne Rita Monahan Foundation has raised $50,000 for ovarian cancer research at the Translational Genomics Research Institute (TGen). Funds from the 2nd annual Tea for TEAL event will support the development of a reliable screening test and precision therapy for ovarian cancer.
Researchers at Fox Chase Cancer Center have isolated an engineered antibody, GS45, that targets the Müllerian Inhibiting Substance Type II Receptor on ovarian cancer cells. This unique target is scarce in normal tissue, reducing the risk of side effects associated with traditional targeted therapies.
Researchers found that stress-activated protein protects fugitive ovarian cancer cells from programmed death, allowing them to escape the primary tumor and metastasize. The study suggests that restoring cancer cells' vulnerability to anoikis could suppress tumor growth and metastasis.
Researchers find that stress hormones can protect ovarian cancer cells from anoikis, promoting tumor growth. Higher levels of activated FAK are linked to accelerated mortality in ovarian cancer patients.
Chronic stress accelerates tumor growth in ovarian cancer patients by protecting cells from anoikis, a process that allows tumor cells to survive and grow. Stress hormones norepinephrine and epinephrine activate the protein FAK, leading to accelerated mortality.
A recent study published in the Journal of Clinical Oncology found that women with breast cancer before age 55 who carry an inherited mutation in BRCA1 or BRCA2 are four times more likely to develop cancer in the breast opposite their initial tumor. The study revealed a higher risk of contralateral breast cancer among younger women wit...
Researchers from the University of Gothenburg found that women with a known Western Swedish mutation in the BRCA1 gene have an increased risk of developing ovarian cancer. The study suggests that women without this mutation do not face an elevated risk, and provides clarity for targeted screenings.
Despite progress in cancer research, the disease remains a leading cause of death in the US. Advances in primary prevention, early detection, and treatment have improved outcomes for many cancers, but significant challenges remain, including the need for improved therapies.
Researchers found that microRNA-31 regulates the protein IFITM-1, which contributes to chemoresistance in ovarian cancer. Identifying this microRNA could lead to a therapeutic target for overcoming chemotherapy resistance.
A new study suggests that elective removal of ovaries during hysterectomy may not be beneficial and could even increase the risk of other health problems. The study analyzed data from over 300,000 women who underwent the procedure, finding a link between oophorectomy and increased risks of coronary artery disease and hip fractures.
Researchers found that GP referrals for gynaecological investigation were delayed for older women with suspected ovarian cancer. Women over 70 years old had a 20-week wait for referral, while those aged 75-79 years had a peak wait of 24 weeks. The discrepancy may be due to differences in data recording and GPs' motivation.
Businessman-philanthropist Foster Friess will match donations up to $50,000 to support TGen's ovarian cancer research. The event has already raised nearly $38,000, with over 500 participants expected.
A new study published in the Journal of the American Dietetic Association found a strong relationship between healthy eating and prolonged ovarian cancer survival. Higher consumption of fruits, vegetables, and healthier grains was associated with improved survival rates.
Dr Clare Scott and Dr Marnie Blewitt have been awarded fellowships worth AU$1.75 million to focus on lymphoma and breast cancer, respectively. Their research aims to improve outcomes for cancer patients by harnessing the body's natural killing machinery.
POSITIVE RESULTS is a comprehensive guidebook for those at high risk of breast and ovarian cancer, providing insights into genetics, diagnosis, and treatment options. The book offers a supportive approach to navigating complex decisions, covering genetic testing, screening, mastectomy, and more.
Researchers at Georgia Tech have developed a potential new treatment against ovarian cancer using magnetic nanoparticles to attach to and remove cancer cells from the body. The technique has shown promising results in both mouse and human cancer samples.
Researchers found that ovarian cancer symptoms are not reliable for detecting the disease at an early stage. In fact, only 1 out of 100 women with symptoms will be diagnosed with ovarian cancer. This study highlights the need for better molecular markers and imaging modalities to improve screening for ovarian cancer.
Researchers at Yale University have discovered that stopping the expression of two genes Lin28 and Oct4 can reduce ovarian cancer cell growth and survival. This could lead to more effective treatments for this deadly form of cancer, which has a high recurrence rate and resistance to treatment.
Researchers discovered a noninvasive contrast-enhanced ultrasound imaging technique that can aid in the detection of early-stage ovarian cancer when combined with proteomic blood analyses. This method has shown high accuracy and the potential to save lives by detecting disease at an early stage.
Researchers found that biomarker levels began to rise 3 years before clinical diagnosis, but became substantially elevated only a year prior. While not accurate enough for early intervention, these markers are associated with modest increases in ovarian cancer risk.
A genetic signature associated with poor patient outcomes could lead to improved therapies for ovarian cancer. The study found that MAGP2, a previously unknown cancer gene, was overexpressed in tumors of patients who died more quickly.
Research from the American Journal of Pathology reveals that glycosaminoglycans contribute to skeletal abnormalities in patients with lysosomal storage diseases. Additionally, αvβ3-integrin expression improves ovarian cancer patient prognosis, while CpG DNA may be a therapeutic candidate for Alzheimer's disease treatment.
A new study finds that women with a deleterious BRCA gene mutation are diagnosed with breast cancer six years earlier than their relatives who also had the disease and/or ovarian cancer. The findings could impact how women at highest risk for breast cancer are counseled and screened in the future.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
The Fox Chase-Penn Ovarian SPORE program will focus on three central concepts in ovarian cancer: epigenetics, predictive biomarkers, and targeted therapeutics. The grant will fund five main research projects and three core facilities to support multidisciplinary research efforts.
A new genetic marker associated with ovarian cancer risk was discovered by a research group led by scientists from the University of Hawaii at Manoa. The marker is present among 32% of women and contributes an estimated 0.7% to ovarian cancer risk, particularly for serous carcinoma subtype.
Researchers at the University of Gothenburg have developed a new treatment that uses a radioactive substance to seek and destroy tumour cells in ovarian cancer patients. The treatment, which has shown no unwanted side-effects in an initial study, aims to provide a more effective alternative to current treatments.